Febuxostat in the therapy of gout: from theory to practice
Gout is a chronic disease that requires permanent urate-lowering therapy. Allopurinol is the gold standard of this therapy. The novel drug febuxostat, a selective xanthine oxidase inhibitor, has been synthesized and introduced into clinical practice in the last 10 years. The paper reviews the litera...
Main Authors: | E. V. Ilyinykh, S. A. Vladimirov, M. S. Eliseev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2018-01-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/800 |
Similar Items
-
Microbiota as a new pathogenetic factor in the development of chronic hyperuricemia and gout. Part 2: gout therapy and the gut microbiota
by: M. S. Eliseev, et al.
Published: (2022-12-01) -
ACR management guidelines for the treatment of gout: What’s new and what’s controversial
by: M. S. Eliseev
Published: (2021-05-01) -
Commentaries on the updated American College of Rheumatology guidelines for the management of gout. Urate-lowering drugs (Part 1)
by: M. S. Eliseev
Published: (2020-09-01) -
Rational use of recommendations for urate-lowering therapy: clinical examples
by: M. S. Eliseev, et al.
Published: (2022-06-01) -
Association of the Q141K polymorphism of the ABCG2 gene with the effectiveness of urate-lowering therapy in patients with gout (a pilot study)
by: M. S. Eliseev, et al.
Published: (2021-12-01)